Therapeutic targeting of complement to modify disease course and improve outcomes in neurological conditions

Seminars in Immunology

Volumn 28, Issue 3, 2016, Pages 292-308

  Brennan, Faith H ^a   Lee, John D ^a   Ruitenberg, Marc J ^a   Woodruff, Trent M ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

C5a; Complement; Neurodegeneration; Neurotrauma; Stroke; Therapeutics

Indexed keywords

COMPLEMENT; COMPLEMENT INHIBITOR;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BRAIN INJURY; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; DISEASE COURSE; HUMAN; HUNTINGTON CHOREA; NEUROLOGIC DISEASE; NONHUMAN; OUTCOME ASSESSMENT; PARKINSON DISEASE; REPERFUSION INJURY; REVIEW; SPINAL CORD INJURY; TRAUMATIC BRAIN INJURY; BRAIN; CLINICAL TRIAL (TOPIC); DEGENERATIVE DISEASE; DISEASE EXACERBATION; IMMUNOLOGY; INJURY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEUROPROTECTION; PATHOLOGY; TREATMENT OUTCOME;

BRAIN; CLINICAL TRIALS AS TOPIC; COMPLEMENT ACTIVATION; COMPLEMENT INACTIVATING AGENTS; COMPLEMENT SYSTEM PROTEINS; DISEASE PROGRESSION; HUMANS; MOLECULAR TARGETED THERAPY; NEURODEGENERATIVE DISEASES; NEUROPROTECTION; TREATMENT OUTCOME; WOUNDS AND INJURIES;

EID: 84961908117     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2016.03.015     Document Type: Review

References (198)

1. [1] Menken, M., Munsat, T.L., Toole, J.F., The global burden of disease study: implications for neurology. Arch. Neurol. 57 (2000), 418–420.
2. [2] Amor, S., Puentes, F., Baker, D., van der Valk, P., Inflammation in neurodegenerative diseases. Immunology 129 (2010), 154–169.
3. [3] Ricklin, D., Hajishengallis, G., Yang, K., Lambris, J.D., Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11 (2010), 785–797.
4. [4] Alper, C.A., Johnson, A.M., Birtch, A.G., Moore, F.D., Human C′3: evidence for the liver as the primary site of synthesis. Science 163 (1969), 286–288.
5. [5] Orsini, F., De Blasio, D., Zangari, R., Zanier, E.R., De Simoni, M.G., Versatility of the complement system in neuroinflammation, neurodegeneration and brain homeostasis. Front. Cell. Neurosci., 8 p, 2014, p380.
6. [6] Fraser, D.A., Pisalyaput, K., Tenner, A.J., C1q enhances microglial clearance of apoptotic neurons and neuronal blebs: and modulates subsequent inflammatory cytokine production. J. Neurochem. 112 (2010), 733–743.
7. [7] Paidassi, H., Tacnet-Delorme, P., Garlatti, V., et al. C1q binds phosphatidylserine and likely acts as a multiligand-bridging molecule in apoptotic cell recognition. J. Immunol. 180 (2008), 2329–2338.
8. [8] Nepomuceno, R.R., Tenner, A.J., C1qRP, the C1q receptor that enhances phagocytosis, is detected specifically in human cells of myeloid lineage, endothelial cells, and platelets. J. Immunol. 160 (1998), 1929–1935.
9. [9] Galvan, M.D., Greenlee-Wacker, M.C., Bohlson, S.S., C1q and phagocytosis: the perfect complement to a good meal. J. Leukoc. Biol. 92 (2012), 489–497.
10. [10] Skoda, D., Kranda, K., Bojar, M., et al. Antibody formation against beta-tubulin class III in response to brain trauma. Brain Res. Bull. 68 (2006), 213–216.
11. [11] Zhang, Z., Zoltewicz, J.S., Mondello, S., et al. Human traumatic brain injury induces autoantibody response against glial fibrillary acidic protein and its breakdown products. PLoS One, 9 p, 2014, pe92698.
12. [12] Ankeny, D.P., Guan, Z., Popovich, P.G., B cells produce pathogenic antibodies and impair recovery after spinal cord injury in mice. J. Clin. Invest. 119 (2009), 2990–2999.
13. [13] Ten, V.S., Yao, J., Ratner, V., et al. Complement component c1q mediates mitochondria-driven oxidative stress in neonatal hypoxic-ischemic brain injury. J. Neurosci. 30 (2010), 2077–2087.
14. [14] Vegh, Z., Kew, R.R., Gruber, B.L., Ghebrehiwet, B., Chemotaxis of human monocyte-derived dendritic cells to complement component C1q is mediated by the receptors gC1qR and cC1qR. Mol. Immunol. 43 (2006), 1402–1407.
15. [15] Nauta, A.J., Trouw, L.A., Daha, M.R., et al. Direct binding of C1q to apoptotic cells and cell blebs induces complement activation. Eur. J. Immunol. 32 (2002), 1726–1736.
16. [16] Muller-Eberhard, H.J., Polley, M.J., Calcott, M.A., Formation and functional significance of a molecular complex derived from the second and the fourth component of human complement. J. Exp. Med. 125 (1967), 359–380.
17. [17] Coulthard, L.G., Woodruff, T.M., Is the complement activation product C3a a proinflammatory molecule? Re-evaluating the evidence and the myth. J. Immunol. 194 (2015), 3542–3548.
18. [18] Dyer, J.K., Bourque, J.A., Steeves, J.D., The role of complement in immunological demyelination of the mammalian spinal cord. Spinal Cord 43 (2005), 417–425.
19. [19] Rawal, N., Pangburn, M.K., Formation of high affinity C5 convertase of the classical pathway of complement. J. Biol. Chem. 278 (2003), 38476–38483.
20. [20] Harboe, M., Ulvund, G., Vien, L., Fung, M., Mollnes, T.E., The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin. Exp. Immunol. 138 (2004), 439–446.
21. [21] Tenner, A.J., Robinson, S.L., Ezekowitz, R.A., Mannose binding protein (MBP) enhances mononuclear phagocyte function via a receptor that contains the 126,000 M(r) component of the C1q receptor. Immunity 3 (1995), 485–493.
22. [22] Rawal, N., Rajagopalan, R., Salvi, V.P., Activation of complement component C5: comparison of C5 convertases of the lectin pathway and the classical pathway of complement. J. Biol. Chem. 283 (2008), 7853–7863.
23. [23] Selander, B., Martensson, U., Weintraub, A., et al. Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2. J. Clin. Invest. 116 (2006), 1425–1434.
24. [24] Veerhuis, R., Nielsen, H.M., Tenner, A.J., Complement in the brain. Mol. Immunol. 48 (2011), 1592–1603.
25. [25] Guo, R.F., Ward, P.A., Role of C5a in inflammatory responses. Annu. Rev. Immunol. 23 (2005), 821–852.
26. [26] Mukherjee, P., Pasinetti, G.M., Complement anaphylatoxin C5a neuroprotects through mitogen-activated protein kinase-dependent inhibition of caspase 3. J. Neurochem. 77 (2001), 43–49.
27. [27] Brennan, F.H., Gordon, R., Lao, H.W., et al. The complement receptor C5aR controls acute inflammation and astrogliosis following spinal cord injury. J. Neurosci. 35 (2015), 6517–6531.
28. [28] Pavlovski, D., Thundyil, J., Monk, P.N., et al. Generation of complement component C5a by ischemic neurons promotes neuronal apoptosis. FASEB J. 26 (2012), 3680–3690.
29. [29] Thundyil, J., Pavlovski, D., Hsieh, Y.H., et al. C5a receptor (CD88) inhibition improves hypothermia-induced neuroprotection in an in vitro ischemic model. Neuromolecular Med. 14 (2012), 30–39.
30. [30] Ingersoll, S.A., Martin, C.B., Barnum, S.R., Martin, B.K., CNS-specific expression of C3a and C5a exacerbate demyelination severity in the cuprizone model. Mol. Immunol. 48 (2010), 219–230.
31. [31] Jacob, A., Hack, B., Chen, P., Quigg, R.J., Alexander, J.J., C5a/CD88 signaling alters blood-brain barrier integrity in lupus through nuclear factor-kappaB. J. Neurochem. 119 (2011), 1041–1051.
32. [32] Fonseca, M.I., Ager, R.R., Chu, S.H., et al. Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J. Immunol. 183 (2009), 1375–1383.
33. [33] Woodruff, T.M., Lee, J.D., Noakes, P.G., Role for terminal complement activation in amyotrophic lateral sclerosis disease progression. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), E3–4.
34. [34] Woodruff, T.M., Costantini, K.J., Crane, J.W., et al. The complement factor C5a contributes to pathology in a rat model of amyotrophic lateral sclerosis. J. Immunol. 181 (2008), 8727–8734.
35. [35] Woodruff, T.M., Ager, R.R., Tenner, A.J., Noakes, P.G., Taylor, S.M., The role of the complement system and the activation fragment C5a in the central nervous system. Neuromolecular Med. 12 (2010), 179–192.
36. [36] Li, R., Coulthard, L.G., Wu, M.C., Taylor, S.M., Woodruff, T.M., C5L2: a controversial receptor of complement anaphylatoxin, C5a. FASEB J. 27 (2013), 855–864.
37. [37] Podack, E.R., Tschoop, J., Muller-Eberhard, H.J., Molecular organization of C9 within the membrane attack complex of complement. Induction of circular C9 polymerization by the C5b-8 assembl. J. Exp. Med. 156 (1982), 268–282.
38. [38] Scolding, N.J., Morgan, B.P., Houston, W.A., et al. Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement. Nature 339 (1989), 620–622.
39. [39] Mead, R.J., Singhrao, S.K., Neal, J.W., Lassmann, H., Morgan, B.P., The membrane attack complex of complement causes severe demyelination associated with acute axonal injury. J. Immunol. 168 (2002), 458–465.
40. [40] Ramaglia, V., King, R.H., Nourallah, M., et al. The membrane attack complex of the complement system is essential for rapid Wallerian degeneration. J. Neurosci. 27 (2007), 7663–7672.
41. [41] Huber-Lang, M., Sarma, J.V., Zetoune, F.S., et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat. Med. 12 (2006), 682–687.
42. [42] Brennan, F.H., Anderson, A.J., Taylor, S.M., Woodruff, T.M., Ruitenberg, M.J., Complement activation in the injured central nervous system: another dual-edged sword?. J. Neuroinflammation, 9, 2012, 137.
43. [43] Gasque, P., Dean, Y.D., McGreal, E.P., VanBeek, J., Morgan, B.P., Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology 49 (2000), 171–186.
44. [44] Rogers, J., Cooper, N.R., Webster, S., et al. Complement activation by beta-amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 89 (1992), 10016–10020.
45. [45] McGeer, P.L., Akiyama, H., Itagaki, S., McGeer, E.G., Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci. Lett. 107 (1989), 341–346.
46. [46] Eikelenboom, P., Hack, C.E., Rozemuller, J.M., Stam, F.C., Complement activation in amyloid plaques in Alzheimer's dementia. Virchows Arch. B. Cell Pathol. Incl. Mol. Pathol. 56 (1989), 259–262.
47. [47] Gasque, P., Julen, N., Ischenko, A.M., et al. Expression of complement components of the alternative pathway by glioma cell lines. J. Immunol. 149 (1992), 1381–1387.
48. [48] Gasque, P., Morgan, B.P., Complement regulatory protein expression by a human oligodendrocyte cell line: cytokine regulation and comparison with astrocytes. Immunology 89 (1996), 338–347.
49. [49] Yang, C., Jones, J.L., Barnum, S.R., Expression of decay-accelerating factor (CD55), membrane cofactor protein (CD46) and CD59 in the human astroglioma cell line, D54-MG, and primary rat astrocytes. J. Neuroimmunol. 47 (1993), 123–132.
50. [50] Kim, Y.U., Kinoshita, T., Molina, H., et al. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein. J. Exp. Med. 181 (1995), 151–159.
51. [51] Gasque, P., Thomas, A., Fontaine, M., Morgan, B.P., Complement activation on human neuroblastoma cell lines in vitro: route of activation and expression of functional complement regulatory proteins. J. Neuroimmunol. 66 (1996), 29–40.
52. [52] Wing, M.G., Zajicek, J., Seilly, D.J., Compston, D.A., Lachmann, P.J., Oligodendrocytes lack glycolipid anchored proteins which protect them against complement lysis. Restoration of resistance to lysis by incorporation of CD59. Immunology 76 (1992), 140–145.
53. [53] Cole, D.S., Hughes, T.R., Gasque, P., Morgan, B.P., Complement regulator loss on apoptotic neuronal cells causes increased complement activation and promotes both phagocytosis and cell lysis. Mol. Immunol. 43 (2006), 1953–1964.
54. [54] Adamson, J., Beswick, A., Ebrahim, S., Is stroke the most common cause of disability?. J. Stroke Cerebrovasc. Dis. 13 (2004), 171–177.
55. [55] Feigin, V.L., Lawes, C.M., Bennett, D.A., Anderson, C.S., Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol. 2 (2003), 43–53.
56. [56] Deb, P., Sharma, S., Hassan, K.M., Pathophysiologic mechanisms of acute ischemic stroke: an overview with emphasis on therapeutic significance beyond thrombolysis. Pathophysiology 17 (2010), 197–218.
57. [57] Szeplaki, G., Szegedi, R., Hirschberg, K., et al. Strong complement activation after acute ischemic stroke is associated with unfavorable outcomes. Atherosclerosis 204 (2009), 315–320.
58. [58] Pedersen, E.D., Loberg, E.M., Vege, E., et al. In situ deposition of complement in human acute brain ischaemia. Scand. J. Immunol. 69 (2009), 555–562.
59. [59] Van Beek, J., Bernaudin, M., Petit, E., et al. Expression of receptors for complement anaphylatoxins C3a and C5a following permanent focal cerebral ischemia in the mouse. Exp. Neurol. 161 (2000), 373–382.
60. [60] Mocco, J., Wilson, D.A., Komotar, R.J., et al. Alterations in plasma complement levels after human ischemic stroke. Neurosurgery 59 (2006), 28–33 (discussion 28–33.).
61. [61] Harhausen, D., Khojasteh, U., Stahel, P.F., et al. Membrane attack complex inhibitor CD59a protects against focal cerebral ischemia in mice. J. Neuroinflammation, 7, 2010, 15.
62. [62] Ten, V.S., Sosunov, S.A., Mazer, S.P., et al. C1q-deficiency is neuroprotective against hypoxic-ischemic brain injury in neonatal mice. Stroke 36 (2005), 2244–2250.
63. [63] Mocco, J., Mack, W.J., Ducruet, A.F., et al. Complement component C3 mediates inflammatory injury following focal cerebral ischemia. Circ. Res. 99 (2006), 209–217.
64. [64] Alawieh, A., Elvington, A., Zhu, H., et al. Modulation of post-stroke degenerative and regenerative processes and subacute protection by site-targeted inhibition of the alternative pathway of complement. J. Neuroinflammation, 12 p, 2015, p247.
65. [65] Arumugam, T.V., Tang, S.C., Lathia, J.D., et al. Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 14104–14109.
66. [66] Cervera, A., Planas, A.M., Justicia, C., et al. Genetically-defined deficiency of mannose-binding lectin is associated with protection after experimental stroke in mice and outcome in human stroke. PLoS One, 5 p, 2010, pe8433.
67. [67] Morrison, H., Frye, J., Davis-Gorman, G., et al. The contribution of mannose binding lectin to reperfusion injury after ischemic stroke. Curr. Neurovasc. Res. 8 (2011), 52–63.
68. [68] Vogel, C.W., Fritzinger, D.C., Cobra venom factor: structure, function, and humanization for therapeutic complement depletion. Toxicon 56 (2010), 1198–1222.
69. [69] Vasthare, U.S., Barone, F.C., Sarau, H.M., et al. Complement depletion improves neurological function in cerebral ischemia. Brain Res. Bull. 45 (1998), 413–419.
70. [70] Dodds, W.J., Pickering, R.J., The effect of cobra venom factor on hemostasis in guinea pigs. Blood 40 (1972), 400–411.
71. [71] Figueroa, E., Gordon, L.E., Feldhoff, P.W., Lassiter, H.A., The administration of cobra venom factor reduces post-ischemic cerebral injury in adult and neonatal rats. Neurosci. Lett. 380 (2005), 48–53.
72. [72] Cowell, R.M., Plane, J.M., Silverstein, F.S., Complement activation contributes to hypoxic-ischemic brain injury in neonatal rats. J. Neurosci. 23 (2003), 9459–9468.
73. [73] Lew, S.M., Gross, C.E., Bednar, M.M., et al. Complement depletion does not reduce brain injury in a rabbit model of thromboembolic stroke. Brain Res. Bull. 48 (1999), 325–331.
74. [74] Imm, M.D., Feldhoff, P.W., Feldhoff, R.C., Lassiter, H.A., The administration of complement component C9 augments post-ischemic cerebral infarction volume in neonatal rats. Neurosci. Lett. 325 (2002), 175–178.
75. [75] Lassiter, H.A., Feldhoff, R.C., Dabhia, N., Parker, J.C. Jr., Feldhoff, P.W., Complement inhibition does not reduce post-hypoxic-ischemic cerebral injury in 21-day-old rats. Neurosci. Lett. 302 (2001), 37–40.
76. [76] Weisman, H.F., Bartow, T., Leppo, M.K., et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249 (1990), 146–151.
77. [77] Morgan, B.P., Harris, C.L., Complement: a target for therapy in inflammatory and degenerative diseases. Nat. Rev. Drug Discov. 14 (2015), 857–877.
78. [78] Lazar, H.L., Bokesch, P.M., van Lenta, F., et al. Soluble human complement receptor 1 limits ischemic damage in cardiac surgery patients at high risk requiring cardiopulmonary bypass. Circulation 110 (2004), II274–9.
79. [79] Huang, J., Kim, L.J., Mealey, R., et al. Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein. Science 285 (1999), 595–599.
80. [80] Mocco, J., Mack, W.J., Ducruet, A.F., et al. Preclinical evaluation of the neuroprotective effect of soluble complement receptor type 1 in a nonhuman primate model of reperfused stroke. J. Neurosurg. 105 (2006), 595–601.
81. [81] Ducruet, A.F., Mocco, J., Mack, W.J., et al. Pre-clinical evaluation of an sLe x-glycosylated complement inhibitory protein in a non-human primate model of reperfused stroke. J. Med. Primatol. 36 (2007), 375–380.
82. [82] Elvington, A., Atkinson, C., Zhu, H., et al. The alternative complement pathway propagates inflammation and injury in murine ischemic stroke. J. Immunol. 189 (2012), 4640–4647.
83. [83] De Simoni, M.G., Rossi, E., Storini, C., et al. The powerful neuroprotective action of C1-inhibitor on brain ischemia-reperfusion injury does not require C1q. Am. J. Pathol. 164 (2004), 1857–1863.
84. [84] De Simoni, M.G., Storini, C., Barba, M., et al. Neuroprotection by complement (C1) inhibitor in mouse transient brain ischemia. J. Cereb. Blood Flow Metab. 23 (2003), 232–239.
85. [85] Storini, C., Rossi, E., Marrella, V., et al. C1-inhibitor protects against brain ischemia-reperfusion injury via inhibition of cell recruitment and inflammation. Neurobiol. Dis. 19 (2005), 10–17.
86. [86] Heimann, A., Takeshima, T., Horstick, G., Kempski, O., C1-esterase inhibitor reduces infarct volume after cortical vein occlusion. Brain Res. 838 (1999), 210–213.
87. [87] Heydenreich, N., Nolte, M.W., Gob, E., et al. C1-inhibitor protects from brain ischemia-reperfusion injury by combined antiinflammatory and antithrombotic mechanisms. Stroke 43 (2012), 2457–2467.
88. [88] Akita, N., Nakase, H., Kaido, T., Kanemoto, Y., Sakaki, T., Protective effect of C1 esterase inhibitor on reperfusion injury in the rat middle cerebral artery occlusion model. Neurosurgery 52 (2003), 395–400 (discussion 400-1.).
89. [89] Gesuete, R., Storini, C., Fantin, A., et al. Recombinant C1 inhibitor in brain ischemic injury. Ann. Neurol. 66 (2009), 332–342.
90. [90] Huang, Y., Qiao, F., Atkinson, C., Holers, V.M., Tomlinson, S., A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J. Immunol. 181 (2008), 8068–8076.
91. [91] Orsini, F., Villa, P., Parrella, S., et al. Targeting mannose-binding lectin confers long-lasting protection with a surprisingly wide therapeutic window in cerebral ischemia. Circulation 126 (2012), 1484–1494.
92. [92] Ducruet, A.F., Hassid, B.G., Mack, W.J., et al. C3a receptor modulation of granulocyte infiltration after murine focal cerebral ischemia is reperfusion dependent. J. Cereb. Blood Flow Metab. 28 (2008), 1048–1058.
93. [93] Jarlestedt, K., Rousset, C.I., Stahlberg, A., et al. Receptor for complement peptide C3a: a therapeutic target for neonatal hypoxic-ischemic brain injury. FASEB J. 27 (2013), 3797–3804.
94. [94] Mathieu, M.C., Sawyer, N., Greig, G.M., et al. The C3a receptor antagonist SB 290157 has agonist activity. Immunol. Lett. 100 (2005), 139–145.
95. [95] Wu, M.C., Brennan, F.H., Lynch, J.P., et al. The receptor for complement component C3a mediates protection from intestinal ischemia-reperfusion injuries by inhibiting neutrophil mobilization. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 9439–9444.
96. [96] Finch, A.M., Wong, A.K., Paczkowski, N.J., et al. Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a. J. Med. Chem. 42 (1999), 1965–1974.
97. [97] March, D.R., Proctor, L.M., Stoermer, M.J., et al. Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activity. Mol. Pharmacol. 65 (2004), 868–879.
98. [98] Woodruff, T.M., Pollitt, S., Proctor, L.M., et al. Increased potency of a novel complement factor 5a receptor antagonist in a rat model of inflammatory bowel disease. J. Pharmacol. Exp. Ther. 314 (2005), 811–817.
99. [99] Kim, G.H., Mocco, J., Hahn, D.K., et al. Protective effect of C5a receptor inhibition after murine reperfused stroke. Neurosurgery 63 (2008), 122–125 (discussion 125-6).
100. [100] Morgan, M., Bulmer, A.C., Woodruff, T.M., et al. Pharmacokinetics of a C5a receptor antagonist in the rat after different sites of enteral administration. Eur. J. Pharm. Sci. 33 (2008), 390–398.
101. [101] Woodruff, T.M., Crane, J.W., Proctor, L.M., et al. Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration. FASEB J. 20 (2006), 1407–1417.
102. [102] Costa, C., Zhao, L., Shen, Y., et al. Role of complement component C5 in cerebral ischemia/reperfusion injury. Brain Res. 1100 (2006), 142–151.
103. [103] Kasuya, H., Shimizu, T., Activated complement components C3a and C4a in cerebrospinal fluid and plasma following subarachnoid hemorrhage. J. Neurosurg. 71 (1989), 741–746.
104. [104] Stahel, P.F., Morganti-Kossmann, M.C., Perez, D., et al. Intrathecal levels of complement-derived soluble membrane attack complex (sC5b-9) correlate with blood-brain barrier dysfunction in patients with traumatic brain injury. J. Neurotrauma 18 (2001), 773–781.
105. [105] Lindsberg, P.J., Ohman, J., Lehto, T., et al. Complement activation in the central nervous system following blood–brain barrier damage in man. Ann. Neurol. 40 (1996), 587–596.
106. [106] Hua, Y., Xi, G., Keep, R.F., Hoff, J.T., Complement activation in the brain after experimental intracerebral hemorrhage. J. Neurosurg. 92 (2000), 1016–1022.
107. [107] Bellander, B.M., Singhrao, S.K., Ohlsson, M., Mattsson, P., Svensson, M., Complement activation in the human brain after traumatic head injury. J. Neurotrauma 18 (2001), 1295–1311.
108. [108] You, Z., Yang, J., Takahashi, K., et al. Reduced tissue damage and improved recovery of motor function after traumatic brain injury in mice deficient in complement component C4. J. Cereb. Blood Flow Metab. 27 (2007), 1954–1964.
109. [109] Neher, M.D., Rich, M.C., Keene, C.N., et al. Deficiency of complement receptors CR2/CR1 in Cr2(−)/(−) mice reduces the extent of secondary brain damage after closed head injury. J. Neuroinflammation, 11 p, 2014, p95.
110. [110] Leinhase, I., Holers, V.M., Thurman, J.M., et al. Reduced neuronal cell death after experimental brain injury in mice lacking a functional alternative pathway of complement activation. BMC Neurosci., 7 p, 2006, p55.
111. [111] Sewell, D.L., Nacewicz, B., Liu, F., et al. Complement C3 and C5 play critical roles in traumatic brain cryoinjury: blocking effects on neutrophil extravasation by C5a receptor antagonist. J. Neuroimmunol. 155 (2004), 55–63.
112. [112] Yang, S., Nakamura, T., Hua, Y., et al. The role of complement C3 in intracerebral hemorrhage-induced brain injury. J. Cereb. Blood Flow Metab. 26 (2006), 1490–1495.
113. [113] Yager, P.H., You, Z., Qin, T., et al. Mannose binding lectin gene deficiency increases susceptibility to traumatic brain injury in mice. J. Cereb. Blood Flow Metab. 28 (2008), 1030–1039.
114. [114] Xi, G., Hua, Y., Keep, R.F., Younger, J.G., Hoff, J.T., Systemic complement depletion diminishes perihematomal brain edema in rats. Stroke 32 (2001), 162–167.
115. [115] Bodmer, D., Vaughan, K.A., Zacharia, B.E., Hickman, Z.L., Connolly, E.S., The molecular mechanisms that promote edema after intracerebral hemorrhage. Transl. Stroke Res. 3 (2012), 52–61.
116. [116] Kaczorowski, S.L., Schiding, J.K., Toth, C.A., Kochanek, P.M., Effect of soluble complement receptor-1 on neutrophil accumulation after traumatic brain injury in rats. J. Cereb. Blood Flow Metab. 15 (1995), 860–864.
117. [117] Leinhase, I., Schmidt, O.I., Thurman, J.M., et al. Pharmacological complement inhibition at the C3 convertase level promotes neuronal survival, neuroprotective intracerebral gene expression, and neurological outcome after traumatic brain injury. Exp. Neurol. 199 (2006), 454–464.
118. [118] Rancan, M., Morganti-Kossmann, M.C., Barnum, S.R., et al. Central nervous system-targeted complement inhibition mediates neuroprotection after closed head injury in transgenic mice. J. Cereb. Blood Flow Metab. 23 (2003), 1070–1074.
119. [119] Alexander, J.J., Bao, L., Jacob, A., et al. Administration of the soluble complement inhibitor Crry-Ig, reduces inflammation and aquaporin 4 expression in lupus cerebritis. Biochim. Biophys. Acta 1639 (2003), 169–176.
120. [120] Rosengard, A.M., Alonso, L.C., Korb, L.C., et al. Functional characterization of soluble and membrane-bound forms of vaccinia virus complement control protein (VCP). Mol. Immunol. 36 (1999), 685–697.
121. [121] Jha, P., Kotwal, G.J., Vaccinia complement control protein: multi-functional protein and a potential wonder drug. J. Biosci. 28 (2003), 265–271.
122. [122] Hicks, R.R., Keeling, K.L., Yang, M.Y., et al. Vaccinia virus complement control protein enhances functional recovery after traumatic brain injury. J. Neurotrauma 19 (2002), 705–714.
123. [123] Longhi, L., Perego, C., Ortolano, F., et al. C1-inhibitor attenuates neurobehavioral deficits and reduces contusion volume after controlled cortical impact brain injury in mice. Crit. Care Med. 37 (2009), 659–665.
124. [124] Leinhase, I., Rozanski, M., Harhausen, D., et al. Inhibition of the alternative complement activation pathway in traumatic brain injury by a monoclonal anti-factor B antibody: a randomized placebo-controlled study in mice. J. Neuroinflammation, 4 p, 2007, p13.
125. [125] Rynkowski, M.A., Kim, G.H., Garrett, M.C., et al. C3a receptor antagonist attenuates brain injury after intracerebral hemorrhage. J. Cereb. Blood Flow Metab. 29 (2009), 98–107.
126. [126] Garrett, M.C., Otten, M.L., Starke, R.M., et al. Synergistic neuroprotective effects of C3a and C5a receptor blockade following intracerebral hemorrhage. Brain Res. 1298 (2009), 171–177.
127. [127] Li, G., Fan, R.M., Chen, J.L., et al. Neuroprotective effects of argatroban and C5a receptor antagonist (PMX53) following intracerebral haemorrhage. Clin. Exp. Immunol. 175 (2014), 285–295.
128. [128] Hepburn, N.J., Williams, A.S., Nunn, M.A., et al. In vivo characterization and therapeutic efficacy of a C5-specific inhibitor from the soft tick Ornithodoros moubata. J. Biol. Chem. 282 (2007), 8292–8299.
129. [129] Fluiter, K., Opperhuizen, A.L., Morgan, B.P., Baas, F., Ramaglia, V., Inhibition of the membrane attack complex of the complement system reduces secondary neuroaxonal loss and promotes neurologic recovery after traumatic brain injury in mice. J. Immunol. 192 (2014), 2339–2348.
130. [130] Ruseva, M.M., Ramaglia, V., Morgan, B.P., Harris, C.L., An anticomplement agent that homes to the damaged brain and promotes recovery after traumatic brain injury in mice. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 14319–14324.
131. [131] Anderson, A.J., Robert, S., Huang, W., Young, W., Cotman, C.W., Activation of complement pathways after contusion-induced spinal cord injury. J. Neurotrauma 21 (2004), 1831–1846.
132. [132] Galvan, M.D., Luchetti, S., Burgos, A.M., et al. Deficiency in complement C1q improves histological and functional locomotor outcome after spinal cord injury. J. Neurosci. 28 (2008), 13876–13888.
133. [133] Qiao, F., Atkinson, C., Kindy, M.S., et al. The alternative and terminal pathways of complement mediate post-traumatic spinal cord inflammation and injury. Am. J. Pathol. 177 (2010), 3061–3070.
134. [134] Guo, Q., Li, S., Liang, Y., et al. Effects of C3 deficiency on inflammation and regeneration following spinal cord injury in mice. Neurosci. Lett. 485 (2010), 32–36.
135. [135] Qiao, F., Atkinson, C., Song, H., et al. Complement plays an important role in spinal cord injury and represents a therapeutic target for improving recovery following trauma. Am. J. Pathol. 169 (2006), 1039–1047.
136. [136] Reynolds, D.N., Smith, S.A., Zhang, Y.P., et al. Vaccinia virus complement control protein reduces inflammation and improves spinal cord integrity following spinal cord injury. Ann. N. Y. Acad. Sci. 1035 (2004), 165–178.
137. [137] Li, L.M., Li, J.B., Zhu, Y., Fan, G.Y., Soluble complement receptor type 1 inhibits complement system activation and improves motor function in acute spinal cord injury. Spinal Cord 48 (2010), 105–111.
138. [138] Beck, K.D., Nguyen, H.X., Galvan, M.D., et al. Quantitative analysis of cellular inflammation after traumatic spinal cord injury: evidence for a multiphasic inflammatory response in the acute to chronic environment. Brain 133 (2010), 433–447.
139. [139] Li, L., Xiong, Z.Y., Qian, Z.M., et al. Complement C5a is detrimental to histological and functional locomotor recovery after spinal cord injury in mice. Neurobiol. Dis. 66 (2014), 74–82.
140. [140] Ulndreaj, A., Marbourg, J.M., Vidal, P.M., The complement receptor C5aR has a dual: time-Dependent effect on the outcome of spinal cord injury. J. Neurosci. 35 (2015), 12325–12327.
141. [141] Brennan, F.H., Ruitenberg, M.J., Targeting acute inflammation to complement spinal cord repair. Neural Regen. Res. 10 (2015), 1596–1598.
142. [142] Brookmeyer, R., Gray, S., Kawas, C., Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am. J. Public Health 88 (1998), 1337–1342.
143. [143] Wong, C.W., Quaranta, V., Glenner, G.G., Neuritic plaques and cerebrovascular amyloid in Alzheimer disease are antigenically related. Proc. Natl. Acad. Sci. U. S. A. 82 (1985), 8729–8732.
144. [144] Grundke-Iqbal, I., Iqbal, K., Tung, Y.C., et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. U. S. A. 83 (1986), 4913–4917.
145. [145] Eikelenboom, P., Stam, F.C., Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study. Acta Neuropathol. 57 (1982), 239–242.
146. [146] Shen, Y., Lue, L., Yang, L., et al. Complement activation by neurofibrillary tangles in Alzheimer's disease. Neurosci. Lett. 305 (2001), 165–168.
147. [147] Yasojima, K., Schwab, C., McGeer, E.G., McGeer, P.L., Up-regulated production and activation of the complement system in Alzheimer's disease brain. Am. J. Pathol. 154 (1999), 927–936.
148. [148] Afagh, A., Cummings, B.J., Cribbs, D.H., Cotman, C.W., Tenner, A.J., Localization and cell association of C1q in Alzheimer's disease brain. Exp. Neurol. 138 (1996), 22–32.
149. [149] Yang, L.B., Li, R., Meri, S., Rogers, J., Shen, Y., Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease. J. Neurosci. 20 (2000), 7505–7509.
150. [150] Zhou, J., Fonseca, M.I., Pisalyaput, K., Tenner, A.J., Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer's disease. J. Neurochem. 106 (2008), 2080–2092.
151. [151] Fonseca, M.I., Zhou, J., Botto, M., Tenner, A.J., Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. J. Neurosci. 24 (2004), 6457–6465.
152. [152] Stephan, A.H., Madison, D.V., Mateos, J.M., et al. A dramatic increase of C1q protein in the CNS during normal aging. J. Neurosci. 33 (2013), 13460–13474.
153. [153] Boyett, K.W., DiCarlo, G., Jantzen, P.T., et al. Increased fibrillar beta-amyloid in response to human clq injections into hippocampus and cortex of APP + PS1 transgenic mice. Neurochem. Res. 28 (2003), 83–93.
154. [154] Tenner, A.J., Fonseca, M.I., The double-edged flower: roles of complement protein C1q in neurodegenerative diseases. Adv. Exp. Med. Biol. 586 (2006), 153–176.
155. [155] Benoit, M.E., Tenner, A.J., Complement protein C1q-mediated neuroprotection is correlated with regulation of neuronal gene and microRNA expression. J. Neurosci. 31 (2011), 3459–3469.
156. [156] Benoit, M.E., Hernandez, M.X., Dinh, M.L., et al. C1q-induced LRP1B and GPR6 proteins expressed early in Alzheimer disease mouse models, are essential for the C1q-mediated protection against amyloid-beta neurotoxicity. J. Biol. Chem. 288 (2013), 654–665.
157. [157] Maier, M., Peng, Y., Jiang, L., et al. Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J. Neurosci. 28 (2008), 6333–6341.
158. [158] Wyss-Coray, T., Yan, F., Lin, A.H., et al. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 10837–10842.
159. [159] Lian, H., Yang, L., Cole, A., et al. NFkappaB-activated astroglial release of complement C3 compromises neuronal morphology and function associated with Alzheimer's disease. Neuron 85 (2015), 101–115.
160. [160] Woodruff, T.M., Tenner, A.J., A commentary on: nFkappaB-Activated astroglial release of complement C3 compromises neuronal morphology and function associated with alzheimer's disease. a cautionary note regarding C3aR. Front. Immunol., 6 p, 2015, p220.
161. [161] Fonseca, M.I., McGuire, S.O., Counts, S.E., Tenner, A.J., Complement activation fragment C5a receptors CD88 and C5L2, are associated with neurofibrillary pathology. J. Neuroinflammation, 10 p, 2013, p25.
162. [162] Ager, R.R., Fonseca, M.I., Chu, S.H., et al. Microglial C5aR (CD88) expression correlates with amyloid-beta deposition in murine models of Alzheimer's disease. J. Neurochem. 113 (2010), 389–401.
163. [163] Bruijn, L.I., Cleveland, D.W., Mechanisms of selective motor neuron death in ALS: insights from transgenic mouse models of motor neuron disease. Neuropathol. Appl. Neurobiol. 22 (1996), 373–387.
164. [164] Cozzolino, M., Ferri, A., Carri, M.T., Amyotrophic lateral sclerosis: from current developments in the laboratory to clinical implications. Antioxid. Redox Signal. 10 (2008), 405–443.
165. [165] Boillee, S., Vande Velde, C., Cleveland, D.W., ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron 52 (2006), 39–59.
166. [166] J.D. Lee, J.Y. Lee, S.M. Taylor, P.G. Noakes, T.M. Woodruff, Innate Immunity in ALS. [Book chapter], M.H. Maurer, (2012) pp. 393–412.
167. [167] Apostolski, S., Nikolic, J., Bugarski-Prokopljevic, C., et al. Serum and CSF immunological findings in ALS. Acta Neurol. Scand. 83 (1991), 96–98.
168. [168] Goldknopf, I.L., Sheta, E.A., Bryson, J., et al. Complement C3c and related protein biomarkers in amyotrophic lateral sclerosis and Parkinson's disease. Biochem. Biophys. Res. Commun. 342 (2006), 1034–1039.
169. [169] Kawamata, T., Akiyama, H., Yamada, T., McGeer, P.L., Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am. J. Pathol. 140 (1992), 691–707.
170. [170] Donnenfeld, H., Kascsak, R.J., Bartfeld, H., Deposits of IgG and C3 in the spinal cord and motor cortex of ALS patients. J. Neuroimmunol. 6 (1984), 51–57.
171. [171] Sta, M., Sylva-Steenland, R.M., Casula, M., et al. Innate and adaptive immunity in amyotrophic lateral sclerosis: evidence of complement activation. Neurobiol. Dis. 42 (2011), 211–220.
172. [172] Annunziata, P., Volpi, N., High levels of C3c in the cerebrospinal fluid from amyotrophic lateral sclerosis patients. Acta Neurol. Scand. 72 (1985), 61–64.
173. [173] Mantovani, S., Gordon, R., Macmaw, J.K., et al. Elevation of the terminal complement activation products C5a and C5b-9 in ALS patient blood. J. Neuroimmunol. 276 (2014), 213–218.
174. [174] Lee, J.D., Kamaruzaman, N.A., Fung, J.N., et al. Dysregulation of the complement cascade in the hSOD1G93A transgenic mouse model of amyotrophic lateral sclerosis. J. Neuroinflammation, 10 p, 2013, p119.
175. [175] Ferraiuolo, L., Heath, P.R., Holden, H., et al. Microarray analysis of the cellular pathways involved in the adaptation to and progression of motor neuron injury in the SOD1 G93A mouse model of familial ALS. J. Neurosci. 27 (2007), 9201–9219.
176. [176] Fukada, Y., Yasui, K., Kitayama, M., et al. Gene expression analysis of the murine model of amyotrophic lateral sclerosis: studies of the Leu126delTT mutation in SOD1. Brain Res. 1160 (2007), 1–10.
177. [177] Heurich, B., El Idrissi, N.B., Donev, R.M., et al. Complement upregulation and activation on motor neurons and neuromuscular junction in the SOD1 G93A mouse model of familial amyotrophic lateral sclerosis. J. Neuroimmunol. 235 (2011), 104–109.
178. [178] Lobsiger, C.S., Boillee, S., Cleveland, D.W., Toxicity from different SOD1 mutants dysregulates the complement system and the neuronal regenerative response in ALS motor neurons. Proc. Natl. Acad. Sci. U.S.A. 104 (2007), 7319–7326.
179. [179] Chiu, I.M., Phatnani, H., Kuligowski, M., et al. Activation of innate and humoral immunity in the peripheral nervous system of ALS transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 106 (2009), 20960–20965.
180. [180] Lobsiger, C.S., Boillee, S., Pozniak, C., et al. C1q induction and global complement pathway activation do not contribute to ALS toxicity in mutant SOD1 mice. Proc. Natl. Acad. Sci. U.S.A. 110 (2013), E4385–92.
181. [181] Humayun, S., Gohar, M., Volkening, K., et al. The complement factor C5a receptor is upregulated in NFL-/- mouse motor neurons. J. Neuroimmunol. 210 (2009), 52–62.
182. [182] Graveland, G.A., Williams, R.S., DiFiglia, M., Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science 227 (1985), 770–773.
183. [183] Mangiarini, L., Sathasivam, K., Seller, M., et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87 (1996), 493–506.
184. [184] MacDonald, M.E., Ambrose, C.M., Duyao, M.P., et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72 (1993), 971–983.
185. [185] DiFiglia, M., Sapp, E., Chase, K.O., et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277 (1997), 1990–1993.
186. [186] Dauer, W., Przedborski, S., Parkinson's disease: mechanisms and models. Neuron 39 (2003), 889–909.
187. [187] Moore, D.J., West, A.B., Dawson, V.L., Dawson, T.M., Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci. 28 (2005), 57–87.
188. [188] Dalrymple, A., Wild, E.J., Joubert, R., et al. Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. J. Proteome Res. 6 (2007), 2833–2840.
189. [189] Leblhuber, F., Walli, J., Jellinger, K., et al. Activated immune system in patients with Huntington's disease. Clin. Chem. Lab. Med. 36 (1998), 747–750.
190. [190] Wang, Y., Hancock, A.M., Bradner, J., et al. Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease Alzheimer's disease, and multiple-system atrophy. Am. J. Pathol. 178 (2011), 1509–1516.
191. [191] Loeffler, D.A., Camp, D.M., Conant, S.B., Complement activation in the Parkinson's disease substantia nigra: an immunocytochemical study. J. Neuroinflammation, 3, 2006, 29.
192. [192] Singhrao, S.K., Neal, J.W., Morgan, B.P., Gasque, P., Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease. Exp. Neurol. 159 (1999), 362–376.
193. [193] Hodges, A., Strand, A.D., Aragaki, A.K., et al. Regional and cellular gene expression changes in human Huntington's disease brain. Hum. Mol. Genet. 15 (2006), 965–977.
194. [194] Larkin, P.B., Muchowski, P.J., Genetic deficiency of complement component 3 does not alter disease progression in a mouse model of Huntington's disease. J. Huntingtons Dis. 1 (2012), 107–118.
195. [195] Liang, Y., Li, S., Guo, Q., et al. Complement 3-deficient mice are not protected against MPTP-induced dopaminergic neurotoxicity. Brain Res. 1178 (2007), 132–140.
196. [196] Meisel, C., Schwab, J.M., Prass, K., Meisel, A., Dirnagl, U., Central nervous system injury-induced immune deficiency syndrome. Nat. Rev. Neurosci. 6 (2005), 775–786.
197. [197] Thurman, J.M., Rohrer, B., Noninvasive detection of complement activation through radiologic imaging. Adv. Exp. Med. Biol. 735 (2013), 271–282.
198. [198] Thurman, J.M., Kulik, L., Orth, H., et al. Detection of complement activation using monoclonal antibodies against C3d. J. Clin. Invest. 123 (2013), 2218–2230.